Revmatologie s.r.o.

Revmatologie s.r.o. conducts extensive research on conditions such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, aiming to improve long‑term outcomes and joint health.

• Long‑term safety and tolerability of bimekizumab in axial spondyloarthritis
• Head‑to‑head efficacy of abatacept versus adalimumab in early seropositive rheumatoid arthritis
• Structural knee changes evaluated with LNA043 in symptomatic osteoarthritis
• Combination therapy of lutikizumab and risankizumab for active psoriatic arthritis

The site’s multidisciplinary team of seven investigators integrates clinical expertise with patient‑centered care to advance therapeutic options for musculoskeletal disorders.

Clinical programs focus on autoimmune conditions including systemic lupus erythematosus and Sjögren’s syndrome, evaluating novel biologics that target disease‑driving pathways.

• Ianalumab (VAY736) in active systemic lupus erythematosus
• BIIB059 (litifilimab) assessing efficacy in lupus patients on standard of care
• Abiprubart investigation for symptom relief in Sjögren’s disease
• Safety monitoring of ianalumab regimens in systemic lupus erythematosus extension study

By enrolling patients across disease severity spectrums, the center seeks to identify treatments that reduce systemic inflammation and improve quality of life.

The clinic explores therapies for inflammatory skin‑joint disorders, notably psoriasis and its associated arthritis, with an emphasis on biologic agents that modulate immune signaling.

• Bimekizumab efficacy and safety in active psoriatic arthritis
• Tildrakizumab comparative studies in anti‑TNF‑naïve and anti‑TNF‑experienced psoriatic arthritis cohorts
• Guselkumab treatment outcomes for active psoriatic arthritis
• Deucravacitinib versus placebo in biologic‑naïve psoriatic arthritis participants

These investigations aim to broaden therapeutic choices for patients whose skin and joint symptoms remain uncontrolled by existing options.

Trials address the intersection of metabolic health and musculoskeletal impairment, including participants who are overweight or obese and experience joint pain.

• Eloralintide (LY3841136) study targeting knee osteoarthritis pain in overweight individuals
• Body weight change as a secondary endpoint in metabolic‑focused arthritis trials
• Evaluation of lifestyle‑adjunct interventions alongside pharmacologic therapy

The research underscores the importance of weight management as a complementary strategy to improve joint function and reduce disease burden.

While primary focus lies in rheumatology, the site also monitors ocular manifestations that can arise from systemic autoimmune activity, such as in uveitis associated with rheumatic disorders.

• Observational study of eye inflammation in patients with axial spondyloarthritis
• Assessment of retinal health in systemic lupus erythematosus cohorts

These efforts help identify early eye involvement and guide interdisciplinary management between rheumatologists and ophthalmologists.

Research includes evaluation of oral and salivary gland involvement in autoimmune conditions, particularly Sjögren’s syndrome, to improve diagnostic accuracy and patient comfort.

• Quantitative salivary flow testing in Sjögren’s disease participants
• Correlation of oral dryness scores with systemic disease activity indices
• Impact of targeted therapies on oral manifestations in autoimmune cohorts

By integrating dental assessments, Revmatologie s.r.o. aims to deliver comprehensive care that addresses both systemic and oral health challenges.